Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
about
Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell LymphomaClinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyondClinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma.Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?Cell of origin of transformed follicular lymphomaThe three CARMA sisters: so different, so similar: a portrait of the three CARMA proteins and their involvement in human disorders.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.Citrullination/Methylation Crosstalk on Histone H3 Regulates ER-Target Gene Transcription.Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas.ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis.Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum.Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis
P2860
Q26853170-03DAD804-C3C6-433D-9C5E-F235FA6A4362Q27027493-C0BBFA23-1DA5-457F-914C-07BDBB8CE950Q33687549-518C37E2-4B22-4608-9869-7E064C56EFEEQ35691157-B4E85CA2-2E89-4BCF-9F94-DD83F09CFED3Q36140942-4BBB445A-7448-4FF8-AFBD-93A7464BD536Q36225164-13482304-676B-46B8-B2FA-8DCC1F45384BQ38174486-C9D8F1E1-B308-469F-9A83-8965D2C9019EQ38240579-D45F1C11-16CB-4BA3-A60E-D3CF13731955Q38664822-E06748DC-EA8D-4062-8514-928ABCCBF23CQ38729502-EA4AB119-7733-4D4C-99F6-A15297FDF9C2Q38796261-B8A98192-61A4-4F87-87F2-A9D22AB45BBBQ38811964-C9954F0C-84C9-4CEC-837C-8535D9022A58Q38945255-E2912F7F-850E-4950-A5AC-8C026A65AAF6Q38959472-AF3D372A-5028-4599-A3D8-7AF8D5137FC1Q40353159-D2CE4C50-697D-44DE-BAC9-AF81031C510AQ42384499-26FA45EB-7095-48DD-90B4-06B240A2B347Q47152822-E309A292-A55D-40F4-B184-812274E268A8Q48222205-476CAE0B-4AE2-4646-80FE-0BD9AFB02B56Q50234821-AC3CDB0F-2FE4-4F9B-8772-01E415F0B7EFQ51286673-C6E13B57-CCA7-460C-8D2E-CD305AF1E1E1Q53567189-4053DEF6-F0AB-4C70-AB3D-17D475FDE4B1Q58777266-4555499A-819F-4050-9E4E-8FAA8F173E4C
P2860
Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Targetable activating mutation ...... diffuse large B-cell lymphoma.
@en
Targetable activating mutation ...... diffuse large B-cell lymphoma.
@nl
type
label
Targetable activating mutation ...... diffuse large B-cell lymphoma.
@en
Targetable activating mutation ...... diffuse large B-cell lymphoma.
@nl
prefLabel
Targetable activating mutation ...... diffuse large B-cell lymphoma.
@en
Targetable activating mutation ...... diffuse large B-cell lymphoma.
@nl
P2093
P2860
P356
P1476
Targetable activating mutation ...... diffuse large B-cell lymphoma.
@en
P2093
Abdelilah Bouzelfen
Anne-Lise Ménard
Catherine Maingonnat
Christian Bastard
Elodie Bohers
Fabrice Jardin
Hervé Tilly
Marion Alcantara
Pascaline Etancelin
Philippe Bertrand
P2860
P304
P356
10.1002/GCC.22126
P577
2013-11-05T00:00:00Z